MicroDose Technologies enters into a multiproduct development and licensing agreement with pharmaceutical giant Novartis. MicroDose Technologies, a developer of drug-delivery systems based in Monmouth Junction, today announced that it has entered into a multiproduct development and licensing agreement for its dry-powder inhaler with pharmaceutical giant Novartis of Bridgewater. The MicroDose inhaler is a handheld, breath-activated device that delivers a range of compounds independent of inhalation effort. MicroDose could receive up to $125 million from Novartis in milestones for the successful development of the first five products.